Celebrating 25 years Est 1999-2024
*Across 3 years $2158.56 only $1079.28
Genmab to Present at Citi’s Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; November 25, 2024 Genmab A/S (Nasdaq: GMAB) announced...
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S...
Genmab Announces Financial Results for the First Nine Months of 2024 November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine...
Genmab to Present at Jefferies London Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 Genmab A/S (Nasdaq: GMAB) announced...
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 Company Announcement Net sales of DARZALEX® in the third quarter...
Major Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 – Genmab...
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S...
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and...
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S...
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; August 26, 2024 Genmab A/S...
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma...
Genmab Announces Changes to its Executive Committee Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company...
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.